PharmGKB summary: sertraline pathway, pharmacokinetics
Authors:
- 1 February 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 30 (2) , 26-33
Abstract
No abstract availableKeywords
This publication has 145 references indexed in Scilit:
- Effects of Sertraline and Fluoxetine on P-Glycoprotein at Barrier Sites: In Vivo and In Vitro ApproachesPLOS ONE, 2013
- Selective serotonin reuptake inhibitors pathwayPharmacogenetics and Genomics, 2009
- Decreased Susceptibility of the Cytochrome P450 2B6 Variant K262R to Inhibition by Several Clinically Important DrugsDrug Metabolism and Disposition, 2009
- Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressantsBritish Journal of Clinical Pharmacology, 2007
- Effect of Sertraline on the Pharmacokinetics and Protein Binding of Diazepam in Healthy VolunteersClinical Pharmacokinetics, 1997
- Effect of Sertraline on Protein Binding of WarfarinClinical Pharmacokinetics, 1997
- A Study of the Potential Effect of Sertraline on the Pharmacokinetics and Protein Binding of TolbutamideClinical Pharmacokinetics, 1997
- Pharmacokinetics of Sertraline and its N-Demethyl Metabolite in Elderly and Young Male and Female VolunteersClinical Pharmacokinetics, 1997
- An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.Journal of Clinical Investigation, 1990
- On central effects of serotonin re-uptake inhibitors: Quantitative EEG and psychometric studies with sertraline and zimelidineJournal of Neural Transmission, 1986